Similar articles

• Oral and topical 5-aminosalicylic acid (mesalazine) in inducing and maintaining remission in mild-moderate relapse of ulcerative colitis: one-year randomised multicentre trial.

  Paoluzi P, D'Albasio G, Pera A, Bianchi Porro G, Paoluzi OA, Pica R, Cottone M, Miglioli M, Prantera C, Sturniolo G, Ardizzone S. Paoluzi P, et al. Dig Liver Dis. 2002 Nov;34(11):787-93. doi: 10.1016/s1590-8658(02)80072-x. Dig Liver Dis. 2002. PMID: 12546514 Clinical Trial.
• Once daily vs multiple daily mesalamine therapy for mild to moderate ulcerative colitis: a meta-analysis.

  Li W, Zhang ZM, Jiang XL. Li W, et al. Colorectal Dis. 2016 Jul;18(7):O214-23. doi: 10.1111/codi.13393. Colorectal Dis. 2016. PMID: 27214762 Review.
• Review article: induction therapy for patients with active ulcerative colitis.

  Travis SP. Travis SP. Aliment Pharmacol Ther. 2006 Sep;24 Suppl 1:10-6. doi: 10.1111/j.1365-2036.2006.03070.x. Aliment Pharmacol Ther. 2006. PMID: 16939424 Review.
• Can oral 5-aminosalicylic acid be administered once daily in the treatment of mild-to-moderate ulcerative colitis? A meta-analysis of randomized-controlled trials.

  Zhu Y, Tang RK, Zhao P, Zhu SS, Li YG, Li JB. Zhu Y, et al. Eur J Gastroenterol Hepatol. 2012 May;24(5):487-94. doi: 10.1097/MEG.0b013e328350fc81. Eur J Gastroenterol Hepatol. 2012. PMID: 22465970
• Treatment of distal ulcerative colitis: now the patients have the choice.

  Schölmerich J. Schölmerich J. Ital J Gastroenterol Hepatol. 1999 Nov;31(8):685-7. Ital J Gastroenterol Hepatol. 1999. PMID: 10730560 No abstract available.